EAH.L

ECO Animal Health Group Plc
Eco Animal Health Gp - Director/PDMR Shareholding
30th August 2024, 14:07
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3786C
Eco Animal Health Group PLC
30 August 2024
 

30 August 2024

 

A green and white sign with black text Description automatically generated

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Director/PDMR Dealings

 

ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has been notified that on 30 August 2024, David Hallas, Chief Executive Officer, purchased 18,181 ordinary shares of 5 pence each ("Ordinary Shares") at a price of 110 pence per share.

 

Following this transaction, David Hallas' total interest in the Company is 109,334 Ordinary Shares, representing approximately 0.16 per cent. of the Company's issued share capital.

 

Details of the transactions can be found in the Notification of Dealing Form below.

 

 

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)


020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

 

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

 

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

David Hallas

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

ECO Animal Health Group plc

b)

 

LEI

 

 

2138009XN9DJ3YP70B55

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each

 



Identification code

GB0032036807 



b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




110 pence

 

18,181







d)

 

Aggregated information

N/A - Single transaction



- Aggregated volume




- Price




e)

 

Date of the transaction

 

 

30 August 2024

 

 

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSGDILGXDGSG]]>
TwitterFacebookLinkedIn